Sex Differences in Neoplastic Progression in Barrett’s Esophagus: A Multicenter Prospective Cohort Study
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Study Population
2.3. Ethics
2.4. Statistical Analysis
3. Results
3.1. Baseline Characteristics
3.2. Risk of Neoplastic Progression
3.3. Time to Neoplastic Progression
3.4. Stage Distribution of Neoplastic Progression
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Spechler, S.J. Barrett’s esophagus and esophageal adenocarcinoma: Pathogenesis, diagnosis, and therapy. Med. Clin. N. Am. 2002, 86, 1423–1445. [Google Scholar] [CrossRef]
- Shaheen, N.; Ransohoff, D.F. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: Scientific review. JAMA 2002, 287, 1972–1981. [Google Scholar] [CrossRef] [PubMed]
- Steevens, J.; Botterweck, A.A.; Dirx, M.J.; van den Brandt, P.A.; Schouten, L.J. Trends in incidence of oesophageal and stomach cancer subtypes in Europe. Eur. J. Gastroenterol. Hepatol. 2010, 22, 669–678. [Google Scholar] [CrossRef] [PubMed]
- Cook, M.B.; Chow, W.H.; Devesa, S.S. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977–2005. Br. J. Cancer 2009, 101, 855–859. [Google Scholar] [CrossRef] [Green Version]
- Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63, 11–30. [Google Scholar] [CrossRef] [Green Version]
- Cook, M.B.; Wild, C.P.; Forman, D. A systematic review and meta-analysis of the sex ratio for Barrett’s esophagus, erosive reflux disease, and nonerosive reflux disease. Am. J. Epidemiol. 2005, 162, 1050–1061. [Google Scholar] [CrossRef]
- van Blankenstein, M.; Looman, C.W.; Johnston, B.J.; Caygill, C.P. Age and sex distribution of the prevalence of Barrett’s esophagus found in a primary referral endoscopy center. Am. J. Gastroenterol. 2005, 100, 568–576. [Google Scholar] [CrossRef]
- de Jonge, P.J.; van Blankenstein, M.; Looman, C.W.; Casparie, M.K.; Meijer, G.A.; Kuipers, E.J. Risk of malignant progression in patients with Barrett’s oesophagus: A Dutch nationwide cohort study. Gut 2010, 59, 1030–1036. [Google Scholar] [CrossRef] [Green Version]
- Yousef, F.; Cardwell, C.; Cantwell, M.M.; Galway, K.; Johnston, B.T.; Murray, L. The incidence of esophageal cancer and high-grade dysplasia in Barrett’s esophagus: A systematic review and meta-analysis. Am. J. Epidemiol. 2008, 168, 237–249. [Google Scholar] [CrossRef] [Green Version]
- Falk, G.W.; Thota, P.N.; Richter, J.E.; Connor, J.T.; Wachsberger, D.M. Barrett’s esophagus in women: Demographic features and progression to high-grade dysplasia and cancer. Clin. Gastroenterol. Hepatol. 2005, 3, 1089–1094. [Google Scholar] [CrossRef]
- Ford, A.C.; Forman, D.; Reynolds, P.D.; Cooper, B.T.; Moayyedi, P. Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett’s esophagus. Am. J. Epidemiol. 2005, 162, 454–460. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kastelein, F.; Biermann, K.; Steyerberg, E.W.; Verheij, J.; Kalisvaart, M.; Looijenga, L.H.; Stoop, H.A.; Walter, L.; Kuipers, E.J.; Spaander, M.C.; et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett’s oesophagus. Gut 2013, 62, 1676–1683. [Google Scholar] [CrossRef] [PubMed]
- Shaheen, N.J.; Falk, G.W.; Iyer, P.G.; Gerson, L.B.; American College of, G. ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus. Am. J. Gastroenterol. 2016, 111, 30–50, quiz 1. [Google Scholar] [CrossRef] [PubMed]
- Kerkhof, M.; van Dekken, H.; Steyerberg, E.W.; Meijer, G.A.; Mulder, A.H.; de Bruine, A.; Driessen, A.; ten Kate, F.J.; Kusters, J.G.; Kuipers, E.J.; et al. Grading of dysplasia in Barrett’s oesophagus: Substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 2007, 50, 920–927. [Google Scholar] [CrossRef]
- Siersema, P.D.; Bergman, J.J.G.H.M.; van Berge Henegouwen, M.I.; van der Gaast, A.; Hameeteman, W.; van Hillegersberg, R.; ten Kate, F.J.W.; Meijer, S.; Numans, M.E.; Offerhaus, J.W.O.; et al. Richtlijn Barrett’s Esophagus. Nederlandse Vereniging van Maag-Darm-Leverartsen. 2018. Available online: www.mdl.nl (accessed on 26 April 2022).
- Daiko, H.; Kato, K. Updates in the 8th edition of the TNM staging system for esophagus and esophagogastric junction cancer. Jpn. J. Clin. Oncol. 2020, 50, 847–851. [Google Scholar] [CrossRef]
- Sharma, P.; Dent, J.; Armstrong, D.; Bergman, J.J.; Gossner, L.; Hoshihara, Y.; Jankowski, J.A.; Junghard, O.; Lundell, L.; Tytgat, G.N.; et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: The Prague C & M criteria. Gastroenterology 2006, 131, 1392–1399. [Google Scholar]
- R Core Team. R: A Language and Environment for Statistical Computing R Foundation for Statistical Computing V; R Core Team: Vienna, Austria, 2017; Available online: https://www.R-project.org/ (accessed on 21 February 2020).
- Bhat, S.; Coleman, H.G.; Yousef, F.; Johnston, B.T.; McManus, D.T.; Gavin, A.T.; Murray, L.J. Risk of malignant progression in Barrett’s esophagus patients: Results from a large population-based study. J. Natl. Cancer Inst. 2011, 103, 1049–1057. [Google Scholar] [CrossRef] [Green Version]
- Abrams, J.A.; Fields, S.; Lightdale, C.J.; Neugut, A.I. Racial and ethnic disparities in the prevalence of Barrett’s esophagus among patients who undergo upper endoscopy. Clin. Gastroenterol. Hepatol. 2008, 6, 30–34. [Google Scholar] [CrossRef] [Green Version]
- Allen, J.E.; Desai, M.; Roumans, C.A.M.; Vennalaganti, S.; Vennalaganti, P.; Bansal, A.; Falk, G.; Lieberman, D.; Sampliner, R.; Thota, P.; et al. Low Risk of Progression of Barrett’s Esophagus to Neoplasia in Women. J. Clin. Gastroenterol. 2021, 55, 321–326. [Google Scholar] [CrossRef]
- Verbeek, R.E.; Leenders, M.; Ten Kate, F.J.; van Hillegersberg, R.; Vleggaar, F.P.; van Baal, J.W.; van Oijen, M.G.; Siersema, P.D. Surveillance of Barrett’s esophagus and mortality from esophageal adenocarcinoma: A population-based cohort study. Am. J. Gastroenterol. 2014, 109, 1215–1222. [Google Scholar] [CrossRef]
- Gordon, L.G.; Mayne, G.C.; Hirst, N.G.; Bright, T.; Whiteman, D.C.; Australian Cancer Study Clinical Follow-Up Sudy; Watson, D.I. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett’s esophagus. Gastrointest. Endosc. 2014, 79, 242–256.e6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hameeteman, W.; Tytgat, G.N.; Houthoff, H.J.; van den Tweel, J.G. Barrett’s esophagus: Development of dysplasia and adenocarcinoma. Gastroenterology 1989, 96 Pt 1, 1249–1256. [Google Scholar] [CrossRef]
- Mudyanadzo, T.A. Barrett’s Esophagus: A Molecular Overview. Cureus 2018, 10, e3468. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Roumans, C.A.M.; Tomer, A.; Lansdorp-Vogelaar, I.; Biermann, K.; Bruno, M.J.; Steyerberg, E.W.; Spaander, M.C.W.; Rizopoulos, D.; on behalf of the ProBar study group. Personalised dynamic surveillance strategies in barrett’s oesophagus: A multicentre prospective cohort study. UEG J. 2019, 7, 1411–1425. [Google Scholar]
- Roumans, C.A.M.; Naber, S.K.; Omidvari, A.-H.; Kroep, S.; Wijnhoven, B.P.; van der Gaast, A.; de Jonge, P.J.F.; Steyerberg, E.W.; Rizopoulos, D.; Spaander, M.C.W.; et al. The potential of personalized surveillance intervals for Barrett’s Esophagus patients: A microsimulation study. Gastroenterology 2020, 158 (Suppl. S1), S-88. [Google Scholar] [CrossRef]
- Dong, J.; Maj, C.; Tsavachidis, S.; Ostrom, Q.T.; Gharahkhani, P.; Anderson, L.A.; Wu, A.H.; Ye, W.; Bernstein, L.; Borisov, O.; et al. Sex-Specific Genetic Associations for Barrett’s Esophagus and Esophageal Adenocarcinoma. Gastroenterology 2020, 159, 2065–2076.e1. [Google Scholar] [CrossRef]
- Petrick, J.L.; Falk, R.T.; Hyland, P.L.; Caron, P.; Pfeiffer, R.M.; Wood, S.N.; Dawsey, S.M.; Abnet, C.C.; Taylor, P.R.; Guillemette, C.; et al. Association between circulating levels of sex steroid hormones and esophageal adenocarcinoma in the FINBAR Study. PLoS ONE 2018, 13, e0190325. [Google Scholar] [CrossRef] [Green Version]
- Coleman, H.G.; Bhat, S.; Johnston, B.T.; McManus, D.; Gavin, A.T.; Murray, L.J. Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett’s esophagus. Gastroenterology 2012, 142, 233–240. [Google Scholar] [CrossRef] [Green Version]
Variables | Males (n = 639) | Females (n = 229) | p-Value | |
---|---|---|---|---|
FU time (median, IQR) | 7.2 years (3.2–12.3) | 7.1 years (3.7–12.0) | 0.91 | |
n° of FU (median, IQR) | 4.0 (2.0–6.0) | 4.0 (2.0–6.0) | 0.93 | |
Age (median, IQR) | 60 years (52–69) | 65 years (57–71) | <0.001 | |
GERD (%) | 196 (31%) | 70 (31%) | 0.94 | |
PPI use (%) | 526 (82%) | 208 (91%) | 0.03 | |
NSAID use (%) | 28 (4%) | 10 (4%) | 1.00 | |
Smoking (%) | current | 140 (23%) | 36 (16%) | <0.001 |
former | 327 (51%) | 78 (34%) | ||
never | 166 (23%) | 108 (47%) | ||
Alcohol (%) | current | 531 (83%) | 129 (56%) | <0.001 |
ever | 59 (9.2%) | 26 (11%) | ||
never | 44 (6.9%) | 66 (29%) | ||
BMI (median, IQR) | 26.5 kg/m2 (24.7–29.1) | 27.3 kg/m2 (24.8–31.4) | 0.001 | |
Length of BE in cm (median, IQR) | 4.0 (2.0–6.0) | 4.0 (3.0–6.0) | 0.97 | |
Esophagitis present (%) | 62 (9.7%) | 20 (8.7%) | 0.81 |
Neoplastic Progression | Male (n = 639) | Female (n = 229) |
---|---|---|
HGD | 37 (71%) | 4 (44%) |
EAC | 15 (29%) | 5 (56%) |
Total | 52 (100%) | 9 (100%) |
Probability of Neoplastic Progression (HR; 95% CI) * | ||
HGD/EAC | HGD | |
Female | Ref. | Ref. |
Male | 2.26 (1.11; 4.62) | 3.76 (1.33; 10.6) |
Time to Neoplastic Progression (AR; 95% CI) * | ||
HGD/EAC | HGD | |
Female | Ref. | Ref. |
Male | 0.52 (0.29; 0.95) | 0.40 (0.19; 0.86) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Roumans, C.A.M.; Zellenrath, P.A.; Steyerberg, E.W.; Lansdorp-Vogelaar, I.; Doukas, M.; Biermann, K.; Alderliesten, J.; van Ingen, G.; Nagengast, W.B.; Karrenbeld, A.; et al. Sex Differences in Neoplastic Progression in Barrett’s Esophagus: A Multicenter Prospective Cohort Study. Cancers 2022, 14, 3240. https://doi.org/10.3390/cancers14133240
Roumans CAM, Zellenrath PA, Steyerberg EW, Lansdorp-Vogelaar I, Doukas M, Biermann K, Alderliesten J, van Ingen G, Nagengast WB, Karrenbeld A, et al. Sex Differences in Neoplastic Progression in Barrett’s Esophagus: A Multicenter Prospective Cohort Study. Cancers. 2022; 14(13):3240. https://doi.org/10.3390/cancers14133240
Chicago/Turabian StyleRoumans, Carlijn A. M., Pauline A. Zellenrath, Ewout W. Steyerberg, Iris Lansdorp-Vogelaar, Michael Doukas, Katharina Biermann, Joyce Alderliesten, Gert van Ingen, Wouter B. Nagengast, Arend Karrenbeld, and et al. 2022. "Sex Differences in Neoplastic Progression in Barrett’s Esophagus: A Multicenter Prospective Cohort Study" Cancers 14, no. 13: 3240. https://doi.org/10.3390/cancers14133240